At least 50% of @entity1 with @entity308 ( @entity308 ) treated successfully with electroconvulsive therapy (ECT) will experience a relapse within the first year of follow-up. Sleep disturbances are very common in @entity308 and may constitute forerunners of relapse. In this study we tested the hypothesis that @entity2493 , a sleep-promoting hormone, would decrease the 3-month relapse rate after successful ECT. We included in the study @entity1 with @entity308 successfully treated with ECT (post-ECT Hamilton Rating Scale for @entity308 [HRSD] < or = 10). @entity1 were blindly randomized to two groups, one receiving @entity905 + placebo and one receiving @entity905 + @entity2493 . Assessments (HRSD, Brief Psychiatric Rating Scale, Global Assessment of Function Scale, Global @entity308 Scale, Pittsburgh Sleep Quality Index, Mini-Mental State Exam, and pill count) were performed for 12 weeks after ECT. Ten of the 35 @entity1 (28.5%) relapsed during the follow-up period. Relapse rates were similar in both groups of @entity1 . Sleep reports were not improved by @entity2493 . @entity1 who achieved a higher functional state post-ECT relapsed less often. We conclude that the addition of @entity2493 to on-going @entity905 treatment did not have a beneficial effect either on the 3-month outcome post-ECT or on the sleep reports of these @entity1 .

Coadministration of @entity2493 and XXXX does not improve the 3-month outcome following ECT.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'MDD', 'manic depressive disorder'] @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine'] @entity2493 :: ('MESH:D008550', 'Chemical') :: ['melatonin']
@entity905 :: (MESH:D005473,Chemical) :: ['fluoxetine']
